1	Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and
2	Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults
3	
4	Authors: Patrick Yassini, ^{1,2} Mark Hutchens, ³ Yamuna D. Paila, ⁴ Lorraine Schoch, ⁴ Anne Aunins, ⁴ Uma
5	Siangphoe, ⁴ and Robert Paris ^{4,*}
6	Affiliations: ¹ Department of Family and Preventive Medicine, University of California, San Diego,
7	California, USA; ² Site 103, Optimal Research, San Diego, California, USA; ³ Optimal Research, Austin,
8	Texas, USA; ⁴ Infectious Disease Development, Moderna, Inc., Cambridge, Massachusetts, USA.
9	
10	*Corresponding Author:
11	Robert Paris, MD
12	Head, Translational Medicine, Infectious Disease Development
13	Moderna, Inc.
14	200 Technology Square, Cambridge, MA 02139
15	Phone: 617-714-6500
16	Email: robert.paris@modernatx.com
17	
18	Alternative Corresponding Author:
19	Anne Aunins
20	Program Leader, COVID-19 Vaccines
21	Moderna, Inc.
22	200 Technology Square, Cambridge, MA 02139
23	Phone: 617-460-5279
24	Email: anne.aunins@modernatx.com

25 ABSTRACT

- 26 Background. This interim analysis of an ongoing phase I randomized clinical trial evaluated the safety,
- 27 reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA
- 28 (mRNA)-based vaccine encoding 2 segments of the spike protein (ie, receptor binding and N-terminal
- 29 domains).
- 30 *Methods.* Healthy aged adults 18-55 years (n = 104) were randomized (1:1:1:1:1) to receive 2 doses of
- 31 mRNA-1283 (10, 30, or 100 μg) or mRNA-1273 (100 μg) administered 28 days apart, or a single dose of
- 32 mRNA-1283 (100 μg). Safety was assessed and immunogenicity was measured by serum neutralizing
- antibody (nAb) or binding antibody (bAb) responses.
- 34 *Results.* At the interim analysis, no safety concerns were identified and no serious adverse events,
- 35 adverse events of special interest, or deaths were reported. Solicited systemic adverse reactions were
- 36 more frequent with higher dose levels of mRNA-1283 than with mRNA-1273. At day 57, all dose levels of
- the 2-dose mRNA-1283 regimen (including the lowest dose level [10 μg]) induced robust nAb and bAb
- responses that were comparable to those of mRNA-1273 (100 μg).
- 39 *Conclusions.* mRNA-1283 was generally safe in adults, with all dose levels of the 2-dose regimen (10, 30,
- 40 and 100 μ g) eliciting similar immunogenicity as the 2-dose mRNA-1273 regimen (100 μ g).
- 41 Clinical Trials Registration: Clinicaltrials.gov, NCT04813796
- 42
- 43 Keywords: severe acute respiratory syndrome coronavirus-2, COVID-19, vaccination, clinical study,
- 44 mRNA vaccines
- 45

46 INTRODUCTION

47	An unprecedented global response to the coronavirus disease 2019 (COVID-19) pandemic led to the
48	rapid development of vaccines against the causative pathogen, severe acute respiratory syndrome
49	coronavirus-2 (SARS-CoV-2). The messenger RNA (mRNA)-based vaccine mRNA-1273 (SPIKEVAX;
50	Moderna, Inc., Cambridge, MA, USA [1]) is authorized and approved for use in many populations
51	worldwide, available for individuals as young as ≥6 months [2]. In the phase III clinical trial in adults,
52	mRNA-1273 had an acceptable safety profile and was efficacious against symptomatic infection and
53	severe disease [3]. Subsequent post-authorization real-world studies provided evidence of mRNA-1273
54	effectiveness against symptomatic infection and hospitalization [4-6] but demonstrated reduced
55	effectiveness against infection caused by several SARS-CoV-2 variants of concern, including B.1.351
56	(beta), AY lineages (delta), and BA lineages (omicron) [7-9]. A booster dose is recommended in
57	individuals aged ≥12 years to maintain effectiveness [10].
58	The response to the COVID-19 pandemic demonstrated that the mRNA-lipid nanoparticle (LNP)
59	platform affords several advantages, including expeditious development of safe and efficacious vaccines
60	[11]; however, the refrigerated shelf life of some of these vaccines can limit vaccine distribution in
61	certain markets [12-15]. Next-generation mRNA-based SARS-CoV-2 vaccines that offer longer
62	refrigerated shelf life and/or are immunogenic at a lower dose than mRNA-1273 may enable increased
63	mRNA-based vaccine coverage worldwide, potentially further preventing COVID-19–associated
64	morbidity and mortality.
65	mRNA-1283 is one such investigational vaccine candidate, aiming to elicit neutralizing antibodies
66	by encoding 2 segments of the SARS-CoV-2 S protein, including the receptor binding domain (RBD) and
67	the N-terminal domain (NTD) regions, which contain key SARS-CoV-2 neutralization epitopes [16, 17].
68	Comparatively, mRNA-1273 encodes the full-length SARS-CoV-2 S protein. A preclinical evaluation of
69	mRNA-1283 in mice demonstrated comparable protection and immunogenicity characteristics as mRNA-

70	1273 with potential dose-sparing properties, while indicating that the shorter mRNA length within
71	mRNA-1283 may facilitate longer storage under refrigeration than mRNA-1273 [18].
72	Here, we report preliminary safety, reactogenicity, and immunogenicity results for mRNA-1283
73	from a phase I, randomized, observer-blind, dose-ranging study in healthy adults aged 18-55 years.
74	
75	METHODS
/5	METHODS
76	Trial Design and Participants
77	This is an ongoing phase I, randomized, observer-blind study being conducted at 5 sites in the United
78	States to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1283 (NCT04813796).
79	Eligible participants were healthy adults (aged 18-55 years) with negative SARS-CoV-2 serology, no
80	known history of SARS-CoV-2 infection or exposure to SARS-CoV-2 or COVID-19 in the previous 30 days,
81	and were not previously administered any coronavirus vaccine. A full list of the study inclusion/exclusion
82	criteria is in the Supplement .
83	Three dose levels of mRNA-1283 (10 μ g, 30 μ g, and 100 μ g) and 1 dose level of mRNA-1273 (100
84	μ g) were administered on a 2-dose schedule with 28 days between doses; the mRNA-1283 100- μ g dose
85	level was also assessed as a single-dose regimen. Participants were randomly assigned in parallel
86	(1:1:1:1) using interactive response technology (Figure S1; see the Supplement for details).
87	Participants were followed for safety, reactogenicity, and immunogenicity, with a planned interim
88	analysis to evaluate data on ≥80 participants through day 57. After the interim analysis, participants
89	who received the single mRNA-1283 100- μg dose were offered an additional injection of mRNA-1273
90	(100 μg).
91	The protocol was approved by the central institutional review board (Advarra, Inc; Columbia,
92	MD) and the study was conducted in accordance with the protocol, applicable laws and regulatory
93	requirements, the International Council for Harmonization Good Clinical Practice guidelines, and the

- 94 ethical principles derived from the Declaration of Helsinki and Council for International Organizations of
- 95 Medical Sciences International Ethical Guidelines. All participants provided written informed consent
- 96 before any study procedures were conducted.
- 97
- 98 Vaccines
- 99 mRNA-1283 is an mRNA-LNP vaccine encoding for a chimeric protein (NTD-RBD-HATM) comprising the
- 100 SARS-CoV-2 S protein NTD and RBD, linked together by a flexible peptide linker and anchored to a 23-
- 101 amino acid transmembrane domain from influenza hemagglutinin (HATM). mRNA-1273 is an mRNA-LNP
- vaccine encoding for the full-length, 2-proline prefusion stabilized SARS-CoV-2 S protein (S2P). Placebo
- 103 was a 0.9% sodium chloride (normal saline) injection.
- 104 Vaccines were provided as a sterile liquid for injection at 0.2 mg/mL (mRNA-1273) or 0.5 mg/mL
- 105 (mRNA-1283; diluted with 0.9% saline to the appropriate dose) concentrations; all vaccines were
- administered at 0.5-mL dose volume into the deltoid muscle. For the 2-dose regimen, each dose level of
- 107 mRNA-1283 or mRNA-1273 was administered 28 days apart (day 1 and day 29). The 1-dose regimen of
- 108 mRNA-1283 had placebo administered on day 1 and mRNA-1283 (100 μg) administered on day 29.

109

110 **Objectives and Endpoints**

- 111 The primary objective was to evaluate the safety and reactogenicity of mRNA-1283 (10 µg, 30 µg, and
- 112 100 μg) and mRNA-1273 (100 μg), each administered on a 2-dose schedule (28 days apart), and mRNA-
- 113 1283 (100 µg) administered as a single dose. Safety endpoints included solicited local (ie, pain,
- erythema, or hardness at the injection site; or axillary swelling or tenderness) and systemic (ie,
- 115 headache, fatigue, myalgia, arthralgia, nausea, chills, and fever) adverse reactions (ARs) ≤7 days of each
- 116 dose, as recorded by participants using an electronic diary; safety laboratory abnormalities ≤7 days of
- 117 each dose (see the **Supplement**); unsolicited adverse events (AEs) ≤28 days of each dose; and any

118	serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to discontinuation, and AEs of special
119	interest (AESIs) from day 1 to end of study. Safety data were monitored by an unblinded, independent
120	data and safety monitoring board, a blinded internal safety team, and a blinded safety oversight team.
121	This report summarizes interim safety assessments after a median of 127 days (>4 months) after dose 2.
122	Secondary objectives were to evaluate the immunogenicity of mRNA-1283 administered as a 2-
123	dose schedule (10 μg , 30 μg , and 100 μg) or a single dose schedule (100 μg) and mRNA-1273
124	administered as a 2-dose schedule (100 μ g) as measured by nAb titer or level of binding antibody (bAb).
125	Serum nAb titers were measured by a validated lentivirus assay [19, 20] (PsVN assay; see the
126	Supplement) against Wuhan-Hu-1 (with D614G mutation) SARS-CoV-2 or the B.1.351 (beta) variant with
127	a 50% inhibitory dilution; titers against Wuhan-Hu-1 (without D614G mutation) were also measured by a
128	validated live virus 50% microneutralization assay [21] (see the Supplement). Levels of serum bAbs
129	against Wuhan-Hu-1 SARS-CoV-2 were measured by a SARS-CoV-2 Meso Scale Discovery (MSD) 4-PLEX
130	assay (modified 3-PLEX assay [22]; see the Supplement). For this interim analysis, only assessments on
131	samples collected on day 1 (baseline) and days 29, 36, and 57 were summarized.
132	
133	Statistical Analyses
134	Sample size determination is described in the Supplement . Safety was assessed in the safety and
135	solicited safety populations (defined in the Supplement). All safety analyses were summarized according
136	to the actual vaccine received. Safety was descriptively analyzed as counts and percentages.
137	Immunogenicity was assessed in the per-protocol population (defined in the Supplement). For
138	each vaccine group, the geometric mean titer (GMT) or levels of SARS-CoV-2 nAb and bAb were
139	computed at each sampling time point, as well as the geometric mean fold rise (GMFR) of titers or levels
140	from baseline to each post-baseline time point; values were summarized alongside corresponding 95%
141	confidence intervals (CIs) calculated based on the <i>t</i> distribution of the log-transformed values, then

142	back-transformed to the original scale for presentation. The geometric mean ratio (GMR) calculated as
143	the mean of the difference in nAb titers and bAb levels between mRNA-1283 and mRNA-1273 and the
144	corresponding 2-sided 95% CI were provided. Percentages of participants with vaccine seroresponse
145	were also calculated by time point and vaccine group alongside 2-sided 95% CIs using the Clopper-
146	Pearson method. Seroresponse was defined as an increase in titer or level from less than the lower limit
147	of quantification [LLOQ] at baseline to \geq LLOQ, or a \geq 4-fold increase over baseline in participants with
148	pre-existing baseline titers or levels that were ≥LLOQ. All analyses were performed using SAS software,
149	version 9.4 (SAS Institute).
150	
151	RESULTS
152	Participants
153	Between March 11, 2021, and July 28, 2021, a total of 104 participants were randomly assigned to
154	receive 2 doses of mRNA-1283 (10 μg, n=21; 30 μg, n=22; 100 μg, n=21), 1 dose of mRNA-1283 (100 μg;
155	n=18), or 2 doses of mRNA-1273 100 μg (n=22). All randomly assigned participants received dose 1 and
156	75 (91.5%) and 20 participants (90.9%) received dose 2 in the mRNA-1283 and mRNA-1273 groups,
157	respectively (Figure 1). Overall, 68 participants (82.9%) in the mRNA-1283 groups and 18 participants
158	(81.8%) in the mRNA-1273 group were included in the per-protocol immunogenicity population for this
159	interim analysis. Participant baseline demographics are summarized in Table 1 .
160	
161	Safety
162	Solicited Local and Systemic Adverse Reactions
163	Across mRNA-1283 groups, solicited local ARs ≤7 days of vaccination were reported by 6-18 participants

164 (33.3-85.7%) after dose 1 and 12-19 participants (73.7-90.5%) after dose 2 (Figure 2A); 21 (95.5%) and

165 19 mRNA-1273 recipients (95.0%) reported solicited local ARs after dose 1 and dose 2, respectively. The 166 majority of solicited local ARs were mild to moderate (grades 1 and 2), with no grade 4 events reported. 167 Pain at the injection site was most common, reported by >70% of participants across vaccine groups 168 following dose 2. The median duration of solicited local ARs was 2-3 days after mRNA-1283 and 3 days 169 after mRNA-1273. 170 After dose 1, solicited systemic ARs \leq 7 days of vaccination were reported by 7-12 participants 171 (38.9-54.5%) across mRNA-1283 groups and 15 participants (68.2%) in the mRNA-1273 group (Figure 172 **2B**). Systemic ARs were more frequent after dose 2, reported by 9-21 participants (60-100%) across 173 mRNA-1283 groups and 19 participants (95.0%) in the mRNA-1273 group. Headache, fatigue, and myalgia were most frequent. Solicited systemic ARs were predominantly mild to moderate after dose 1 174 175 of mRNA-1283, but increased in severity after dose 2, with 3 to 12 (20.0-63.2%) and 1 to 10 participants 176 (6.7-47.6%) reporting grade 2 and 3 events, respectively; no grade 4 events were reported. Increased 177 severity was predominantly reported at higher mRNA-1283 dose levels. Fever and chills were largely 178 reported after dose 2 and for participants who received mRNA-1283 at higher dose levels. The median 179 duration of solicited systemic ARs was 2-3 days after mRNA-1283 and 2 days after mRNA-1273. 180

181 Unsolicited Adverse Events

No prespecified study pause rules were met, and no SAEs, AESIs, severe AEs, or fatal AEs were reported
≤28 days after any dose of mRNA-1283 or mRNA-1273. Unsolicited treatment-emergent AEs (TEAEs)
were reported by 4-9 participants (22.2-42.9%) across mRNA-1283 groups and 7 participants (31.8%) in
the mRNA-1273 group (**Table 2**). Overall, 2-4 (9.5-19.0%) and 4 participants (18.2%) reported unsolicited
TEAEs considered related to either mRNA-1283 or mRNA-1273, respectively. Across mRNA-1283 groups,
a total of 2-3 participants (9.1-14.3%) reported MAAEs; 2 participants reported vaccine-related MAAES
(n=1, allergic dermatitis [mRNA-1283 30 µg]; n=1, headache, fatigue, arthralgia, and myalgia [mRNA-

189 1283 100 µg]). Three mRNA-1273 recipients (13.6%) reported MAAEs, and 1 MAAE (vomiting, 4.5%) was 190 considered related to vaccination. One participant in the mRNA-1273 group discontinued vaccination 191 because of transient elevation in liver transaminase levels 7 days after dose 1 that subsequently 192 returned to normal, which was considered vaccine-related. Clinical laboratory findings are presented in 193 the Supplement. 194 195 Immunogenicity 196 Serum Neutralizing Antibodies Against SARS-CoV-2 197 For the 2-dose regimen, pseudovirus nAb GMTs to D614G SARS-CoV-2 increased from baseline

after dose 1 (day 29) of mRNA-1273 (100 µg) and all dose levels of mRNA-1283 (10 µg, 30 µg, and 100 198 199 µg; Figure 3A). At 28 days following dose 2 (day 57), pseudovirus nAb GMTs (95% CI) for all dose levels 200 of mRNA-1283 administered were comparable to those of mRNA-1273 (mRNA-1283, 10 µg: 1370 [888-201 2112], 30 μg: 1091 [645-1846], and 100 μg: 1679 [1133-2487]; mRNA-1273: 1190 [826-1713]; Figure 3A; 202 Table S1); generally similar finding were observed against Wuhan-Hu-1 (without D614G mutation) with 203 the live-virus microneutralization assay (Figure S2; Table S1). As measured by pseudovirus nAb titers 204 against D614G, seroresponse at day 57 occurred in 100% of participants in all groups who received 2 205 doses of mRNA vaccines. Geometric mean ratios (95% CI; Table S1) of GMTs for 2-dose regimens of 206 mRNA-1283 versus mRNA-1273 at day 57 were 1.15 (0.67-1.98), 0.92 (0.50-1.70), and 1.41 (0.84-2.38) 207 for the mRNA-1283 10-µg, 30-µg, and 100-µg dose levels, respectively. For the 1-dose mRNA-1283 208 regimen (placebo + mRNA-1283 100 μ g), a slight increase from baseline was observed 28 days after 209 mRNA-1283 administration (day 57) but remained lower than 2-dose regimens; the GMR (95% CI) at day 210 57 relative to 2 doses of mRNA-1273 was 0.05 (0.01-0.18) and seroresponse occurred in 28.6% of 211 participants.

After dose 2, all 2-dose mRNA-1283 groups (10 µg, 30 µg, and 100 µg) had comparable
pseudovirus nAb GMTs to B.1.351 compared with mRNA-1273 (Figure 3B; Table S1). The 1-dose mRNA1283 100 µg regimen did not induce a substantial nAb response to B.1.351 at day 57 (Figure 3B). At day
57, seroresponse to B.1.351 occurred in 61.1%-85.0% and 66.7% of participants in the 2-dose mRNA1283 groups and mRNA-1273 group, respectively (Table S1); 14.3% of participants in the 1-dose mRNA1283 regimen had a seroresponse to B.1.351.

218

219 Serum Binding Antibodies Against SARS-CoV-2

220 For the 2-dose regimens, bAb immunoglobulin G (IgG) responses to Wuhan-Hu-1 full-length S protein

221 were low or undetectable at baseline for all vaccine groups and increased after dose 1 of mRNA-1283

222 (10 μg, 30 μg, and 100 μg) and mRNA-1273 (100 μg; Figure 4A). At 28 days after dose 2 (day 57), bAb

responses were generally comparable between mRNA-1283 and mRNA-1273 regardless of dose level

224 (Figure 4A; Table S2), with GM levels (95% CI) reported as 322,671 (232,477-447,858), 280,454

225 (196,077-401,139), 416,620 (312,082-556,175), and 303,004 (242,750-378,212) for the mRNA-1283 10-

μg, 30-μg, and 100-μg and mRNA-1273 100-μg dose levels, respectively. Seroresponse at day 57

occurred in 100% of mRNA-1283 (all dose levels) or mRNA-1273 100 μg recipients. Similar trends were

observed for bAb IgG responses to Wuhan-Hu-1 S protein RBD and NTD (Figure 4B-C; Table S2), with all

dose levels of mRNA-1283 eliciting similar responses to either domain at day 57 as compared with

230 mRNA-1273; seroresponses were observed in 100% of 2-dose vaccine recipients at day 57.

The 1-dose mRNA-1283 regimen (placebo + mRNA-1283 100 μg) showed an increase from
 baseline in bAb responses to Wuhan-Hu-1 S protein, RBD, and NTD at 28 days after mRNA-1283 was

administered (day 57). GM levels (95% CI) were 15,396 (4855-48,820) for S protein, 9700 (3110-30,252)

for RBD, and 296 (95-919) for NTD; seroresponse against S protein, RBD, and NTD was 92.9%.

235

236 DISCUSSION

237	Here, we presented interim safety and immunogenicity findings of a phase I clinical study in
238	healthy adults of a next-generation SARS-CoV-2 vaccine candidate (mRNA-1283), which encodes the
239	SARS-CoV-2 S protein RBD and NTD segments versus full-length S protein encoded by mRNA-1273.
240	Preliminary findings indicate that all mRNA-1283 dose levels (10 μ g, 30 μ g, and 100 μ g) administered on
241	a 2-dose schedule (28 days apart) were generally safe and elicited robust immune responses that were
242	comparable to mRNA-1273 (100 μ g). The lowest investigated mRNA-1283 dose level (10 μ g) had the
243	most favorable tolerability profile and induced robust nAb and bAb responses to SARS-CoV-2 after dose
244	2 that were similar to those of mRNA-1273. Overall, these findings suggest that a 2-dose regimen of
245	mRNA-1283 at a lower dose level may achieve similar vaccine efficacy to mRNA-1273.
246	No safety concerns were identified and no deaths, SAEs, or AESIs were reported. Both local and
247	systemic ARs after dose 1 of mRNA-1283 were generally mild to moderate, characterized by pain at the
248	injection site, headache, fatigue, and myalgia. After dose 2, solicited systemic ARs generally increased in
249	frequency and severity. Overall, compared with mRNA-1273, solicited systemic ARs occurred more
250	frequently with higher dose levels of mRNA-1283.
251	Following a 2-dose schedule, all mRNA-1283 dose levels (including the lowest dose [10 μ g])
252	induced nAb responses after dose 2 to prototype SARS-CoV-2 that were comparable to mRNA-1273 (100
253	μ g). Notably, the pseudovirus nAb responses after dose 2 of mRNA-1273 in this study align with those
254	among adults in the pivotal phase III trial [23], wherein 2 doses of mRNA-1273 (100 μ g) administered 28
255	days apart were efficacious against symptomatic COVID-19 infection and severe COVID- 19 [3, 24].
256	Additionally, levels of bAb responses to full-length S protein, NTD, and RBD were similar between
257	mRNA-1273 and all mRNA-1283 dose levels at 28 days following dose 2. Our interim phase I findings
258	raise the possibility that a lower mRNA-1283 dose administered via a 2-dose regimen might achieve
259	similar efficacy and effectiveness as mRNA-1273 among adults. Notably, although the 1-dose regimen of

260 mRNA-1283 (100 µg) induced bAb responses at 28 days, levels remained lower than those for 2-dose 261 mRNA-1283 and mRNA-1273 regimens; further, neutralizing responses to D614G SARS-CoV-2 remained 262 low after 1 dose, together supporting a 2-dose schedule of mRNA-1283. These data suggest that higher 263 mRNA-1283 dose levels do not result in higher nAb responses; however, whether this finding extends to 264 T-cell responses is currently being assessed. Because the severity of solicited systemic ARs was increased 265 at the mRNA-1283 100-µg dose level, it remains possible that increased systemic inflammation at higher 266 dose levels, potentially through complex interactions of type 1 interferons or other innate immune 267 effector molecules, may suppress B- and/or T-cell responses and warrants further study [25-27]. The 2-268 dose schedule of mRNA-1283 (all dose levels) and mRNA-1273 also elicited comparable nAb responses 269 to the SARS-CoV-2 B.1.351 variant after dose 2; further studies evaluating variant-specific modifications 270 of mRNA-1283 as a booster dose are currently underway (NCT05137236) [28]. 271 This study was strengthened by its randomized design, which allowed for descriptive 272 comparisons to mRNA-1273, a widely administered SARS-CoV-2 vaccine with known efficacy in 273 preventing COVID-19. A limitation was the small number of participants enrolled. This interim report 274 presents findings through day 57 of an ongoing phase I trial that will continue to evaluate mRNA-1283 275 safety and immunogenicity, including long-term antibody responses to inform on immune response 276 durability, which remains important amid reports of waning immunity within 6 months of mRNA-1273 277 primary vaccination [29, 30]. 278 In conclusion, these preliminary findings support the continued evaluation of mRNA-1283, a

next-generation SARS-CoV-2 vaccine. All dose levels of mRNA-1283 administered via a 2-dose regimen,
28 days apart, were generally safe in healthy adults aged 18-55 years, with the lowest dose level (10 µg)
inducing comparable immunogenicity to the approved mRNA-1273 100 µg regimen. Clinical evaluation
of mRNA-1283 is ongoing to assess the applicability of booster doses at lower dose levels and immune
responses against other SARS-CoV-2 variants.

284 Funding

285 This work was supported by Moderna, Inc.

286

287 Data Sharing Statement

- 288 Upon request, and subject to review, Moderna, Inc. will provide the data that support the findings of
- this study. Subject to certain criteria, conditions, and exceptions, Moderna, Inc. may also provide access
- to the related individual anonymized participant data.

291

292 Acknowledgments

- 293 The authors would like to acknowledge Dr. Murray Kimmel (Optimal Research, Melbourne, Florida,
- USA), Dr. Daniel Brune (Optimal Research, Peoria, Illinois, USA), and Dr. Randall Severance (AES/Optimal
- 295 Research, Chandler, Arizona, USA) for their contributions to the study. Medical writing and editorial
- assistance were provided by Emily Stackpole, PhD, of MEDiSTRAVA in accordance with Good Publication
- 297 Practice (GPP3) guidelines, funded by Moderna, Inc., and under the direction of the authors. Potential
- 298 conflictions of Interest: Y. D. P., L. S., A. A., U. S., and R. P. are employees of and shareholders in

299 Moderna, Inc. P. Y. and M. H. have no conflicts to declare.

300

FDA. Package Insert - SPIKEVAX. https://www.fda.gov/media/155675/download. Date accessed 15 March

302 **REFERENCES**

1.

303

304 2022. **2022**. 305 2. World Health Organization. Interim recommendations for use of the Moderna mRNA-1273 vaccine against 306 COVID-19. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-307 recommendation-mRNA-1273-2021.3. Accessed October 12. 308 3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J 309 Med 2021; 384(5): 403-16. 310 4. Bruxvoort KJ, Sy LS, Qian L, et al. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: 311 Interim results from a prospective observational cohort study. Lancet Reg Health Am 2021: 100134. 312 5. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the 313 B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med 2021. 314 Pilishvili T, Gierke R, Fleming-Dutra KE, et al. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health 6. 315 Care Personnel. N Engl J Med 2021; 385(25): e90. 316 7. Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging 317 variants of SARS-CoV-2: test negative case-control study. BMJ 2021; 375: e068848. 318 8. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness 319 against the SARS-CoV-2 Delta variant in Qatar. Nat Med 2021. 320 9. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta 321 variants. Nat Med 2022. 322 10. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against 323 COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among 324 Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 325 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71(7): 255-63. 326 11. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and 327 clinical translation. Nat Rev Drug Discov 2021; 20(11): 817-38. 328 12. Uddin MN, Roni MA. Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines. Vaccines 329 **2021**; 9(9): 1033. 330 13. Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 331 vaccines: production, affordability, allocation, and deployment. Lancet 2021; 397(10278): 1023-34. 332 14. Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of COVID-19 vaccine in low-333 income countries. NPJ Vaccines 2021; 6(1): 54. 334 15. Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of 335 mRNA vaccine stability. J Pharm Sci 2021; 110(3): 997-1001. 336 Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients 16. 337 define multiple targets of vulnerability. Science 2020; 369(6504): 643-50. 338 17. Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 339 spike. Nature 2020; 584(7821): 450-6. 340 18. Stewart-Jones GBE, Elbashir SM, Wu K, et al. Development of SARS-CoV-2 mRNA vaccines encoding spike 341 N-terminal and receptor binding domains. bioRxiv 2022: 2022.10.07.511319. 342 19. Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies 343 elicited by ancestral spike vaccines. Cell Host Microbe 2021. 344 20. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in 345 healthy adults: an interim analysis. Nat Med 2021. 346 Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled phase 2 trial of the 21. 347 safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 2021; 39(20): 2791-9. 348 22. Chu L, Vrbicky K, Montefiori D, et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an 349 open-label phase 2 trial. Nat Med 2022; 28(5): 1042-9. 350 23. El Sahly HM, Baden LR, Essink B, et al. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 351 COVE Trial. J Infect Dis 2022.

352 353	24.	El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021 .
354 355	25.	McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev
		Immunol 2015 ; 15(2): 87-103.
356	26.	Darrah PA, Hegde ST, Patel DT, et al. IL-10 production differentially influences the magnitude, quality, and
357		protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 2010 ; 207(7): 1421-
358		33.
359	27.	Arunachalam PS, Scott MKD, Hagan T, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in
360		humans. Nature 2021 ; 596(7872): 410-6.
361	28.	ClinicalTrials.gov. A study to evaluate the immunogenicity and safety of mRNA-1283 COVID-19 vaccine
362		boosters. Available at: https://clinicaltrials.gov/ct2/show/NCT05137236 . Accessed January 23.
363	29.	Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in
364		healthy adults: an interim analysis. Nat Med 2021 ; 27(11): 2025-31.
365	30.	Pegu A, O'Connell SE, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced antibodies against
366		SARS-CoV-2 variants. Science 2021 ; 373(6561): 1372-7.
367		

	mRNA-1283				mRNA- 1273
	10 µg (n=21)	30 µg (n=22)	100 µg (n=21)	Placebo + 100 μg (n=18)	100 µg (n=22)
Age, y					
$Mean \pm SD$	38.1 ± 9.5	34.8 ± 10.4	34.8 ± 10.8	33.7 ± 10.4	42.0 ± 10.3
Median (range)	41.0 (23-51)	30.5 (21-54)	36.0 (19-51)	30.5 (19-49)	43.0 (22-55
Sex, n (%)					
Male	9 (42.9)	13 (59.1)	12 (57.1)	12 (66.7)	14 (63.6)
Female	12 (57.1)	9 (40.9)	9 (42.9)	6 (33.3)	8 (36.4)
Race, n (%)					
White	15 (71.4)	16 (72.7)	16 (76.2)	10 (55.6)	16 (72.7)
Black/African American	1 (4.8)	2 (9.1)	1 (4.8)	0	1 (4.5)
Asian	0	1 (4.5)	2 (9.5)	1 (5.6)	1 (4.5)
American Indian or Alaska Native	0	0	0	1 (5.6)	0
Native Hawaiian or Other Pacific Islander	0	0	0	1 (5.6)	0
Multiracial	1 (4.8)	0	0	2 (11.1)	0
Other	0	0	0	0	0
Not reported	4 (19.0)	3 (13.6)	2 (9.5)	3 (16.7)	4 (18.2)
Ethnicity, n (%)					
Not Hispanic or Latino	14 (66.7)	15 (68.2)	16 (76.2)	13 (72.2)	14 (63.6)
Hispanic or Latino	7 (33.3)	7 (31.8)	5 (23.8)	4 (22.2)	7 (31.8)
Not reported	0	0	0	1 (5.6)	1 (4.5)

368 Table 1. Participant baseline demographics (safety population)

Weight, kg					
Mean \pm SD	81.3 ± 14.4	76.9 ± 17.1	73.4 ± 15.5	82.5 ± 19.9	81.5 ± 11.9
Height, cm					
Mean \pm SD	173.5 ± 11.2	171.8 ± 10.0	172.1 ± 12.1	175.0 ± 9.2	172.3 ± 8.4
BMI, kg/m ²					
Mean \pm SD	27.0 ± 3.8	25.9 ± 4.1	24.6 ± 3.3	26.7 ± 4.5	27.5 ± 3.6

370 population.

371 Abbreviations: BMI, body mass index; mRNA, messenger RNA; SD, standard deviation.

Table 2. Summary of unsolicited TEAEs through 28 days following any vaccination (safety

population)

mRNA-1283					mRNA- 1273	
n (%)	10 µg (n=21)	30 µg (n=22)	100 µg (n=21)	Placebo + 100 μg (n=18)	100 µg (n=22)	
All unsolicited TEAEs						
All AEs	8 (38.1)	9 (40.9)	9 (42.9)	4 (22.2)	7 (31.8)	
SAEs	0	0	0	0	0	
Fatal AEs	0	0	0	0	0	
MAAEs	3 (14.3)	2 (9.1)	2 (9.5)	2 (11.1)	3 (13.6)	
AEs leading to vaccination discontinuation	0	0	0	0	1 (4.5)	
AEs leading to study discontinuation	0	0	0	0	0	
Severe	0	0	0	0	0	
AESIs	0	0	0	0	0	
Related unsolicited TEAEs						
All AEs	2 (9.5)	4 (18.2)	4 (19.0)	2 (11.1)	4 (18.2)	
SAEs	0	0	0	0	0	
Fatal AEs	0	0	0	0	0	
MAAEs	0	1 (4.5)	1 (4.8)	0	1 (4.5)	
AEs leading to vaccination discontinuation	0	0	0	0	1 (4.5)	
AEs leading to study discontinuation	0	0	0	0	0	

Severe	0	0	0	0	0
AESIs	0	0	0	0	0

A TEAE is any event not present before exposure to study vaccination or any event already present that worsened in intensity or frequency after exposure.

Abbreviations: AE, adverse event; AESI, adverse event of special interest; MAAE, medically attended adverse

event; mRNA, messenger RNA; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

FIGURE LEGENDS

Figure 1. Participant disposition. One participant in the mRNA-1273 100-µg group discontinued vaccination because of an adverse event, which was considered related to study vaccination. All randomly assigned participants who received dose 1 of the study vaccination were included in the safety population. Reasons for exclusion from the per-protocol immunogenicity population are described in the **Supplementary Materials**.

Abbreviation: mRNA, messenger RNA.

Figure 2. Solicited (A) local and (B) systemic adverse reactions within 7 days of each dose. Percentages are based on participants in the solicited safety population, consisting of all randomly assigned participants receiving ≥1 dose and contributing any solicited adverse reaction data. Number of participants in the dose 1 solicited safety population: mRNA-1283 10 µg, n=21; mRNA-1283 30 µg, n=22; mRNA-1283 100 µg, n=21; placebo + mRNA-1283 100 µg, n=18; and mRNA-1273 100 µg, n=22. Number of participants in the dose 2 solicited safety population: mRNA-1283 10 µg, n=19; mRNA-1283 30 µg, n=20; mRNA-1283 100 µg, n=21; placebo + mRNA-1283 100 µg, n=15; and mRNA-1273 100 µg, n=20. Abbreviation: mRNA, messenger RNA.

Figure 3. Pseudovirus neutralizing antibody ID₅₀ titers against (A) Wuhan-Hu-1 (with D614G mutation) SARS-CoV-2 or (B) B.1.351 variant through day 57. Neutralizing antibody titers on the pseudovirus neutralization assay at ID₅₀ (log scale) are shown for those participants in the per-protocol immunogenicity population. In both panels, boxplots are based on log-transformed values; boxes and horizontal bars denote IQR range and ID₅₀, respectively, with whisker end points equal to the values below or above the median at 1.5 times the IQR. Dots represent individual results and the dotted lines represent either the LLOQ or ULOQ. Antibody values reported as below the LLOQ were replaced by 0.5 x


LLOQ, whereas values greater than the ULOQ were converted to the ULOQ if the actual values were unavailable. In panel A, the LLOQ was 18.5 ($log_{10}[LLOQ] = 1.267$) and the ULOQ was 45118 ($log_{10}[ULOQ] = 4.654$). In panel B, the LLOQ was 19.5 ($log_{10}[LLOQ] = 1.290$) and the ULOQ was 385.7 ($log_{10}[ULOQ] = 2.586$).

Abbreviations: ID₅₀, 50% inhibitory dose; IQR, interquartile range; LLOQ, lower limit of quantification; mRNA, messenger RNA; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; ULOQ, upper limit of quantification.


Figure 4. Binding antibody levels through day 57 specific to Wuhan-Hu-1 SARS-CoV-2 (A) S protein or (B) RBD. Binding IgG antibody levels specific to Wuhan-Hu-1 SARS-CoV-2 S protein (panel A), RBD (panel B), or NTD (panel C) by MSD 4-PLEX assay are shown for those participants in the per-protocol immunogenicity population. In both panels, boxplots are based on log-transformed values; boxes and horizontal bars denote IQR range and GM, respectively, with whisker end points equal to the values below or above the median at 1.5 times the IQR. Individual results are represented as dots and the dotted lines represent either the LLOQ or ULOQ. Antibody values reported as below the LLOQ were replaced by 0.5 x LLOQ, whereas values greater than the ULOQ were converted to the ULOQ if actual values were unavailable. In panel A, the LLOQ was 23 (log₁₀[LLOQ] = 1.362) and the ULOQ was 14000000 (log₁₀[ULOQ] = 7.146). In panel B, the LLOQ was 19 (log₁₀[LLOQ] = 1.279) and the ULOQ was 6000000 (log₁₀[ULOQ] = 6.778).

Abbreviations: ID₅₀, 50% inhibitory dose; IgG, immunoglobulin G; IQR, interquartile range; LLOQ, lower limit of quantification; mRNA, messenger RNA; MSD, Meso Scale Discovery; NTD, N-terminal domain; RBD, receptor binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; ULOQ, upper limit of quantification.


Figure 1.











+ 10 μg mRNA-1283 + 30 μg mRNA-1283 + 100 μg mRNA-1283 + Placebo + 100 μg mRNA-1283 + 100 μg mRNA-1273

